Date(s) - 04/27/2021
11:00 am - 12:00 pm
Please join John Carlin, FSR Patient Advocate and host of the Sarc Fighter podcast, on Tuesday, April 27, at 11:00AM CST (12PM EST, 10AM MT, 9AM PST) as he moderates this panel discussion on sarcoidosis and steroids. Panelists include: Jessica Reid, FSR Patient Advocate, Dr. Elliott Crouser, Chair of FSR’s Scientific Advisory Board, and Dr. Sanjay Shukla, President and CEO of aTyr Pharma. Read more in the press release.
To register, please click here.
John Carlin (moderator) is an award-winning news anchor currently working at WSLS 10 in Roanoke, Virginia. He is the host of the bi-weekly SarcFighter Podcast. He is a FSR Patient Advocate and member of FSR’s Patient Advisory Committee. John is also an avid cyclist, a strong pillar of his local community, a loving husband, father, and grandfather, and a sarcoidosis warrior.
Jessica Reid came to be a proud Sarcoidosis Patient Navigator by way of experience, not only a 18-year Neurosarcoidosis Survivor, but also a Registered Nurse, and recentFamily Nurse Practitioner (FNP) graduate. She has an unstoppable spirit and thoroughly enjoys learning something new every day. Advocating on her own behalf to her healthcare team is second nature. She finds the opportunity to teach others to do the same very exciting. One fun fact about Jessica is that she is a licensed nail tech and aspires to combine her professions in the near future to continue to joyfully serve others. Just as she refused to allow Neurosarcoidosis to stop her from obtaining her Bachelor and Master of Science in Nursing degrees, Jessica aspires to persevere and achieve her Doctor of Nursing Practice (DNP) within the next 5 years. Jessica was born and raised in North Carolina and currently resides in the Triangle Area with her husband, daughter and son. In her spare time, she appreciates volunteering with the Foundation for Sarcoidosis Research (FSR), serving in her church, exercising 3-5 days weekly, listening to music, reading, journaling, and spending quality time with family and friends.
Dr. Elliott Crouser has over 31 years of medical experience and has been a member of FSR’s SAB since 2016. He is a professor of medicine at Ohio State University where he specializes in Pulmonary and Critical Care Medicine with a focus on translational research on systemic inflammatory diseases involving the lungs. In 25 years of supported research, Dr. Crouser’s laboratory has contributed to the publication of more than 100 peer-reviewed manuscripts, including the first efforts to study sarcoidosis disease mechanisms by deeply scrutinizing genetic data (2009) and the first clinical practice guidelines for sarcoidosis which were endorsed by the American Thoracic Society in 2020.
In addition to his research, Dr. Crouser served as the President of the American Association of Sarcoidosis and Other Granulomatous Disorders (AASOG) from 2017-2019 and has advocated for the sarcoidosis community through engagement with the National Institutes of Health.
Sanjay S. Shukla, M.D., M.S. is President and Chief Executive Officer of aTyr Pharma, where he also serves on the Board of Directors, since November 2017. Dr. Shukla previously served as Chief Medical Officer from March 2016 to November 2017. From April 2015 to March 2016, Dr. Shukla worked in an advisory capacity for a number of companies, including as a consultant to aTyr from January 2016 to March 2016. Prior to that, from October 2012 to April 2015, Dr. Shukla served as Vice President and Global Head of Integrated Medical Services for Novartis, a biopharmaceutical company, where he led global medical affairs operations, with oversight for all pharma general medicines therapies, both inline and in development. Dr. Shukla served as Chief Executive Officer of RXMD, a clinical development consultancy that assisted in advancing proof of concept for early stage drug candidates, from April 2009 to September 2012. Prior to that, Dr. Shukla served in a variety of clinical development, data analytics and drug safety roles at Vifor Pharma, a biopharmaceutical company, and Aspreva Pharmaceuticals (acquired by Vifor Pharma). Dr. Shukla received his M.D. from Howard University College of Medicine and his Bachelors of Science in Microbiology and Master of Science in Epidemiology and Biostatistics from the University of Maryland.